UNSPSC 51373340: Morphine/naltrexone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373340 Morphine/naltrexone is a Commodity code that captures state and local procurement of pharmaceutical products including naloxone, generic pharmaceuticals, and over-the-counter medications for public health, community health, and employee benefit programs. The code reflects purchasing activity across health departments, cooperative purchasing alliances, and county health agencies that source pharmaceuticals through competitive bidding, request-for-proposal processes, and multi-state cooperative vehicles. Recent opportunities span naloxone procurement for opioid response initiatives, generic pharmaceutical supply agreements for multi-jurisdiction cooperative purchasing, and exploratory direct-to-manufacturer pharmacy benefit programs at the state level.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Recent activity concentrates in Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's competitive bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually for community health initiatives; MMCAP's request for proposal (S1070000015802, due March 26, 2026) to establish multiple generic pharmaceutical and OTC product contracts with authorized wholesalers for distribution across participating state and local facilities, requiring cGMP and Drug Supply Chain Security Act compliance with pricing weighted 75 percent in evaluation; and the Texas HHS Commission's request for information (HHS0017013, posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. Vendors pursuing this code must support quarterly or regular delivery cycles, maintain FDA compliance and appropriate insurance coverage, and navigate both local procurement portals and multi-state cooperative purchasing systems.